Author: Abhyankar Anita Tapper Elliot Bonder Alan
Publisher: MDPI
E-ISSN: 1424-8247|7|1|18-28
ISSN: 1424-8247
Source: Pharmaceuticals, Vol.7, Iss.1, 2013-12, pp. : 18-28
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Autoimmune liver disease management goals are primarily slowing disease progression and symptomatic treatment. There are few options for curative medical management other than transplant for a spectrum of autoimmune liver disease that encompasses autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis as well as their overlap syndromes. These diseases are managed primarily with immunosuppressive therapy. Herein, we review the current literature, detailing the promise and pitfalls of the recommended immunosuppressive therapy for these challenging diseases.
Related content
By Conca Paolo Cafaro Giovanni De Renzo Amalia Coppola Antonio Cimino Ernesto Tarantino Giovanni
International Journal of Molecular Sciences, Vol. 16, Iss. 6, 2015-06 ,pp. :
By Bai Qing-Xian Huan Yi Wang Jian-Hong Yang Li-Jie Dong Hong-Juan
International Journal of Molecular Sciences, Vol. 13, Iss. 9, 2012-09 ,pp. :
A Nutrigenomic Approach to Non-Alcoholic Fatty Liver Disease
By Dongiovanni Paola Valenti Luca
International Journal of Molecular Sciences, Vol. 18, Iss. 7, 2017-07 ,pp. :